The presently-disclosed subject matter provides compounds and compositions comprising unique analogs of lignans, methods of making such compounds, and methods of using such compounds.
A quaternary multi-dimensional nanoparticle (qMDNP) includes (a) a nanoparticle, of a cyclodextrin and biocompatible polymer, having a biocompatible shell protecting an internal core wherein the cyclodextrin is selected from a group consisting of (a positively charged functional group)-substituted cyclodextrin, (a negatively charged functional group)-substituted cyclodextrin, and combinations thereof, (b) a polyion adapted to stabilize the internal core containing components with various charges and (c) a therapeutic agent entrapped in the cavity of the cyclodextrin protected in the internal core of the nanoparticle.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
3.
CROSS-GAP-NANOPORE HETEROSTRUCTURE DEVICE AND METHOD FOR IDENTIFYING CHEMICAL SUBSTANCE
A heterostructure device and method allow for detection and identification of a chemical substance. The device includes one or more atomically-thin conducting layers and one or more atomically-thin insulating layers including one or more nanogaps that cross and form one or more nanopores.
The development of lead-free high performing novel piezoelectric materials could allow for lightweight and non-toxic piezoelectric energy harvesters. Herein, is disclosed novel organic-inorganic hybrid metalates (OIHM) incorporating histammonium salts of HistammoniumMXn, with M being a metal and X being a halide. Composites with non-reactive polymer composites such as polyvinylidene difluoride (PVDF) displayed exhibit excellent flexibility and promising unpoled piezoelectric coefficients.
A method of identifying high frequency oscillations (HFOs) in neural signal data involves detrending the neural signal data, and identifying HFOs through one or more objective and training-free strike tests selected from the group consisting of (i) amplitude, (ii) rhythmicity, and (iii) ringing.
The presently-disclosed subject matter relates to diaminobutoxy-substituted isoflavonoids and their use thereof as mitochondrial complex I inhibitors for the treatment of cancer.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 311/36 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
The presently-disclosed subject matter provides a series of gold (III) macrocyclic compounds, compositions comprising such compounds, methods of making such compounds, and methods of using such compounds.
C07F 9/6596 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having atoms other than oxygen, sulfur, selenium, tellurium, nitrogen or phosphorus as ring hetero atoms
A method of recycling batteries includes steps of: shredding the batteries to generate a shredded battery feed material, wetting the shredded battery feed material with an ammonia carbonate lixiviant to generate a slurry, separating the battery feed material in the slurry into a relatively light fraction material slurry and a relatively heavy fraction material slurry, processing the relatively light fraction material slurry in a first counter current ammoniacal leaching and decanting circuit to produce a first pregnant leaching solution including a soluble lithium (Li) component, and processing the relatively heavy fraction material slurry in a second counter current ammoniacal leaching and decanting circuit to produce a second pregnant leaching solution including, if present in the batteries, soluble nickel (Ni), cobalt (Co), zinc (Zn) and copper (Cu) components and insoluble graphite, iron (Fe), aluminum (Al), manganese (Mn) and rare earth element (REEs) components
Devices, systems, and methods for measuring properties of liquids or surrounding gasses within a sealed container. Some embodiments of the devices, systems, and methods disclosed herein are useful for determining and monitoring alcohol (ethanol) content of a liquid within a sealed container. Some embodiments are also useful for determining and monitoring additional properties of the liquid within the sealed container, such as liquid depth (volume) and/or presence of trace chemicals and flavor components.
Disclosed are methods for delivering a reactive hydroxyl compound, systems comprising a delivery composition comprising a reactive hydroxyl compound and a trigger, and kits which incorporate a reactive hydroxyl compound and a trigger.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
11.
METHODS AND COMPOSITIONS TARGETING NUCLEUS ACCUMBENS-ASSOCIATED PROTEIN-1 FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS
Provided herein are methods of for enhancing or inducing an anti-tumor response or treating an autoimmune disorder by administering a therapeutically effective amount of an inhibitor of NAC 1. Also, provided herein are methods of enhancing effectiveness of a vaccine in a subject by administering to the subject a therapeutically effective amount of an inhibitor of NAC 1. Inhibitors of NAC1 can include a chemical agent, such as a composition containing NIC3, or a biological agent that inhibit the function of NAC1 protein, such as an isolated antibody or its binding fragment thereof that binds to NAC1. Inhibitors of NAC 1 can include a biological agent that reduces the expression of NAC1 gene, such as a NAC 1-targeted siRNA administered as a nanoliposome or a CRISPR/Cas-based genome editing composition targeting the NAC1 Gene.
The present disclosure concerns identification of a Per-Arnt-Sim kinase (PASK) targeting peptide and the application thereof for construction of degrons to selectively inhibit expression of PASK in cell systems. The PASK targeting peptide or PASK interacting motif (PIM) is derived from a region within PASK that interacts with the PAS domains and can contribute to kinase activity. In addition to inhibiting PASK expression, the PIM peptides of the present disclosure can therefore competitively interact with endogenous PAS domains and inhibit PASK activity without necessarily altering PASK expression in the cell.
Compounds and compositions having antifungal activity, and methods of using the antifungal compounds and compositions, are described for use in treating fungal infections.
C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A ventricular assist device includes a cannula including a lumen. An inlet valve on the cannula is in communication with the lumen. An outlet valve on the cannula is in communication with the lumen. A pump is connected to the lumen and adapted to draw blood through the inlet valve from the ventricle into the lumen and deliver blood from the lumen through the outlet valve into an aorta or pulmonary artery of the a patient into which the device is implanted. The ventricular assist device also includes an anchor including (a) a graft adapted to receive and hold the cannula and (b) an anchor retainer carried on a first end of the graft and adapted to secure the anchor to the ventricle wall.
A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
A61M 60/117 - Extracorporeal pumps, i.e. the blood being pumped outside the patient’s body for assisting the heart, e.g. transcutaneous or external ventricular assist devices
A61M 60/268 - Positive displacement blood pumps including a displacement member directly acting on the blood the displacement member being flexible, e.g. membranes, diaphragms or bladders
A61M 60/435 - Details relating to driving for positive displacement blood pumps the force acting on the blood contacting member being hydraulic or pneumatic with diastole or systole switching by valve means located between the blood pump and the hydraulic or pneumatic energy source
A61M 60/538 - Regulation using real-time blood pump operational parameter data, e.g. motor current
A61M 60/554 - Regulation using real-time blood pump operational parameter data, e.g. motor current of blood pressure
A61M 60/861 - Connections or anchorings for connecting or anchoring pumps or pumping devices to parts of the patient’s body
A61M 60/896 - Passive valves, i.e. valves actuated by the blood having flexible or resilient parts, e.g. flap valves
The present disclosure describes methods for machine condition monitoring from unlabeled sensing data. The methods include providing a plurality of sensors including at least one acceleration sensor. The plurality of sensors are adapted for obtaining a plurality of high-frequency time series inputs from an operating rotating machine or machine component. The plurality of high-frequency time series inputs received from the plurality of sensors are subjected to one or more augmentation transformations that diversify the plurality of high-frequency time series inputs without impacting condition information. This provides a plurality of augmented inputs which, by the one or more augmentation transformations, are selected to randomize input amplitude and phase.
An insulating material includes hollow carbon fibers embedded in a matrix material. The insulating material is characterized by a unique combination of stiffness, strength, and insulating properties and has a modulus of elasticity of greater than 150 GPa, a tensile strength of greater than 1,200 MPa and a thermal conductivity of less than about 1 W/mK.
Methods for screening a test compound against multiple cell lines are provided and include the steps of: treating a mixture including cells from multiple cell lines with the test compound; identifying allele frequencies of single nucleotide polymorphisms (SNPs) in the treated mixture and a control mixture including cells from the same cell lines as present in the treated mixture; estimating a proportion of each individual cell line in both the treated mixture and the control mixture; and quantifying the effect of the test compound on each individual cell line using the estimated proportion of each cell line in the treated mixture and the estimated proportion of each cell line in the control mixture. Systems for screening a test compound against multiple cell lines, as well as systems and methods for identifying a proportion of a particular cell line in a mixture including multiple cell lines, are also provided.
A cement clinker composition incorporates calcium fluoride and iron oxide to reduce firing temperatures and increase strength. High fly ash, aluminum dross, aluminum scrap, high aluminum clays and combinations thereof may also be substituted for bauxite in the cement clinker composition
The present disclosure relates to compounds, compositions, and methods useful for treating Parkinson's disease. Alzheimer's disease, and multiple sclerosis.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 411/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
20.
SELF-HEALING SOLID-STATE BATTERY CONFIGURATION AND METHOD OF MANFACTURE THEREOF
An electrode stack for a solid-state battery is provided. The electrode stack includes a cathode. The cathode includes a cathode current collector and a first layer of material applied to the cathode current collector. The first layer of material includes a cathode active material, a first ionomer configured as a first binder, and a conductive material. The electrode stack further includes a solid electrolyte separator layer, including a second ionomer configured as a second binder. The electrode stack further includes an anode including a layer including lithium metal, silicon, or graphite and an anode current collector. One of the first ionomer and the second ionomer includes a shape-memory ionomer configured for selectively restoring the electrode stack to an original shape.
This disclosure relates to the development of nucleotide compositions directed to spliced gene variants that generate circular RNAs that are indicative of Alzheimer's disease. In some aspects, the nucleotides are siRNA compositions. In some aspects, the circular RNA is from a backspliced variant produced from the MAPT gene. The circular RNAs contain multiple microtubule binding domains and feature no frame shift and no stop codon when translated, allowing for consistent production. The siRNA compositions disclosed herein demonstrate good efficacy at silencing expression of the circRNAs. Circular RNAs, including tau circular RNAs exhibit a dramatic increase in translation after undergoing A>I editing, i.e. deamination of adenosines to inosines, which causes the formation and accumulation of pathological proteins. This accumulation can be prevented by siRNAs. In addition, five circular RNAs have been identified that correlate in expression levels with Alzheimer's disease severity. These circRNAs express proteins after adenosine to inosine editing. Part of these circproteins are specific for circular RNAs and could be molecular markers for Alzheimer's disease, accessible from cerebrospinal fluid.
A method of recycling a solar panel includes steps of removing a frame from the solar panel, delaminating a glass cover, silicon wafers and a plastic backing of the solar panel using a green solvent adapted to weaken, rather than dissolve, an adhesive used in lamination of the solar panel thereby generating a delaminated material stream, separating glass of the glass cover from the delaminated material stream, separating the plastic backing from the delaminated material stream thereby generating a concentrated metals stream, electrostatically separating insulator materials and electrically conducting materials from the concentrated metals stream thereby creating an insulator material stream and an electrically conducting material stream and separating silicon from other metals in the electrically conducting material stream.
Methods of treating an individual experiencing or at risk of experiencing an undesired consequence of opioid use, and of treating an individual who is experiencing or at risk of experiencing a craving for an opioid, as well as the use of the NK-1 receptor antagonist, tradipitant, in the treatment of such an individual are disclosed herein.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 9/00 - Medicinal preparations characterised by special physical form
An apparatus for capturing carbon dioxide from an untreated gas stream includes (a) an electrochemical unit adapted for generating an inorganic acid and a CO2-free inorganic solvent, (b) an absorber in communication with the electrochemical unit, the absorber adapted for receiving the untreated gas stream and the CO2-free inorganic solvent and capturing the carbon dioxide in the untreated gas stream as a CO2-rich inorganic solvent, and (c) a mixing tank in communication with the electrochemical unit and the absorber, the mixing tank adapted for mixing the inorganic acid, received from the electrochemical unit, with the CO2-rich inorganic solvent, received from the absorber, and releasing carbon dioxide by acid-base neutralization.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01D 53/32 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
A quality assurance system for a medical accelerator includes a housing, an image plate supported by the housing and an image capture assembly. The image plate is adapted to display a visible light field image and a radiation field generated by the medical accelerator. The image capture assembly is adapted to capture the visible light field image and the radiation field displayed by the image plate.
A method of recycling solar panels, including a frame, glass, silicon wafers, and wiring, incorporates the steps of: (a) delaminating the solar panel by breaking down ethylene-vinyl acetate polymer in the solar panel to generate fumed acetic acid, (b) dissolving silver from the silicon wafers of the solar panel in a metal recovery solution using the fumed acetic acid generated during the delaminating and (c) recovering the dissolved silver from the metal recovery solution.
A packing for gas separation from a liquid absorbent includes a body having a corrugated surface or surface sub-texture adapted to create local turbulence within a liquid absorbent with which the body has been wetted. The body may also has a corrugated profile wherein the surface sub-texture comprises a plurality of individual scallops and the corrugated profile comprises a plurality of individual furrow with between about 2 and about 50 individual scallops per furrow. The packing is useful in a method for gas separation from a liquid absorbent.
Aerogels, based on natural polymers with highly porous interconnected channels containing numerous functional groups having coordination capability with heavy metals for detoxification of wastewater generated by mining and metallurgical operations, are disclosed. Embodiments of the aerogels consist of biodegradable polysaccharides, modified to adjust water sorption capacity, and reinforced with inorganic nanostructures functionalized to be cross-linkable with polymers having light-absorption capacity. The light-to-heat conversion characteristic makes the aerogels applicable for recycling of wastewater in disposal pools using natural solar energy. This technology needs no or minimum energy input for water treatment and can be utilized for a wide range of operation scales, which makes it beneficial for small scale mining and metallurgical operations.
A method of recovering enriched iron fines from bauxite waste includes calcining particles of bauxite waste to form oxygen carrier particles, subjecting the oxygen carrier particles to chemical looping combustion at a temperature of about 950° C.-1,050° C. for energy production and to produce the enriched iron fines as a by-product from the oxygen carrier particles via natural attrition and collecting the enriched iron fines.
This disclosure relates to methods for the prevention and/or treatment of neurological adverse effects caused by viral infections in a subject. In some aspects, the methods include administration of at least one N-methyl-D-aspartic acid receptor (NMDAR) antagonist to a subject as a preventative treatment. In other aspects, the NMDAR antagonists may be used as a treatment following a viral infection or suspected viral infection.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Compositions and methods for converting ghrelin to desacyl-ghrelin include a butyrylcholinesterase (BChE) polypeptide variant. The presently-disclosed subject matter includes compositions and methods for use in directly downregulating ghrelin. In particular, certain embodiments relate to compositions and methods for hydrolyzing/deacylating ghrelin to desacyl-ghrelin and applications thereof in the treatment of disorders involving ghrelin.
Humans and Acanthamoeba Polyphaga Mimivirus share numerous homologous genes, including collagens and collagen-modifying enzymes. To explore the homology, a genome-wide comparison was performed between human and mimivirus using DELTA-BLAST (Domain Enhanced Lookup Time Accelerated BLAST) and identified 190 new mimiviral proteins that share homology with 1236 human proteins. To gain functional insights into mimiviral proteins, the human protein homologs were organized into Gene Ontology (GO) and REACTOME pathways to build a functional network. Collagen and collagen-modifying enzymes form the largest subnetwork with most nodes. Further analysis of this subnetwork identified a putative collagen glycosyltransferase R699. Protein expression test suggested that R699 is highly expressed in E coli, unlike the human collagen-modifying enzymes. Enzymatic activity assays showed that R699 catalyzes the conversion of galactosyl-hydroxylysine to glucosyl-galactosyl-hydroxylysine on collagen using UDP-glucose as a sugar donor, suggesting R699 is a mimiviral collagen galactosylhydroxylysyl glucosyltransferase (GGT). Structural study of R699 produced the first crystal structure of a collagen GGT with uridine diphosphate glucose (UDP-Glc). Sugar moiety of the UDP-Glc resides in a previously unrecognized pocket. Mn2+ coordination and nucleoside-diphosphate binding site are conserved among GGT family members and critical for R699's collagen GGT activity. To facilitate further analysis of human and mimiviral homologous proteins, we presented an interactive and searchable genome-wide comparison app for quickly browsing of human and Acanthamoeba Polyphaga Mimivirus homologs, which is available at RRID Resource ID: SCR_022140 or guolab.shinyapps.io/app-mimivirus-publication/.
A method for treating pulmonary fibrosis (PF) is provided. The method includes administering to a subject in need thereof an effective amount of a compound selected from the group consisting of a glycogen phosphatase inhibitor, an acid alpha-glucosidase (GAA) inhibitor, a glycogen synthase (GYS) inhibitor, a glycogen phosphorylase (GP) inhibitor, and combinations thereof, or a pharmaceutically acceptable salt thereof.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
An intelligent machine vision system for in-process monitoring of wear of a cutting tool includes a machine vision camera, a microscope, and a light source adapted for lighting the cutting tool to allow collection of cutting tool images with the machine vision camera. A CDC cutting machine for in-process monitoring of a cutting tool incorporates this machine camera vision system. Further, a method of in-process monitoring of a machine cutting tool includes the steps of displacing a spindle of the machine cutting tool to position the machine cutting tool held in the spindle for monitoring with a machine vision camera and collecting at least one image of a first cutting edge of the cutting tool.
A method of suppressing perception of smoke or vapor odor from an inhalation-based nicotine delivery device and a method of reducing an urge to use an inhalation-based nicotine delivery device involve exposing a subject to a composition comprising citronellal, methyl-2-methylbutyrate, or combinations thereof. The exposure can involve placing the composition in perceptible olfactory proximity to the subject.
A “smart” tourniquet device includes a fastening strap, a tourniquet tightener and a control module carried on the fastening strap. The control module includes a controller, an information display, an indicator and a power source. The “smart” tourniquet device may be used in a method of occluding blood flow through a body part, to reduce trauma related morbidity and mortality.
A61B 17/00 - Surgical instruments, devices or methods
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
38.
Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer
Indole-substituted quinolines (ISQs) are provided which may include a variety of substituted piperidines. Methods for treating cancers, including c-MYC-driven cancers, are described including administering the ISQs to a subject in need thereof. The compounds may be administered in combination with a polo-like kinase-1 (Plk1) inhibitor. The Plk1 and the compound may be administered in synergistically effective amounts.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
39.
PHENOTHIAZINE DERIVATIVES AND REDOX-FLOW BATTERIES
The presently-disclosed subject includes permanent-charge-bearing phenothiazinc derivatives that are redox-active, have beneficial solubility, and do not require supporting salts when used in redox flow battery applications.
H01M 8/04186 - Arrangements for control of reactant parameters, e.g. pressure or concentration of liquid-charged or electrolyte-charged reactants
C07D 279/26 - [b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom without other substituents attached to the ring system
H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
40.
Compositions and methods for treating retinal degradation
The present disclosure relates to modified nucleoside reverse transcriptase inhibitors (NRTIs), such as
and compositions thereof, as well as methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to modified NRTIs and compositions thereof, as well as methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 411/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
41.
A STAGED-FEED POST-COMBUSTION CO2 CAPTURE TECHNOLOGY FOR A FLUE GAS STREAM
A method of making carbon fibers, includes converting poly (3,4-ethylenedioxythiophene):poly (styrene sulfonate) fibers into the carbon fibers by direct carbonization without previously oxidizing the precursor fibers.
D01F 9/24 - Carbon filamentsApparatus specially adapted for the manufacture thereof by decomposition of organic filaments from polyaddition, polycondensation or polymerisation products from macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
An antigen-presenting dendritic cell membrane derived nanovesicle (CDNV) can be made by incubating a dendritic cell (DC) with an antigen and an agent to activate the DC, thereby generating a mature DC displaying a major histocompatibility complex class I (MHC) presenting the antigen, and fragmenting the membrane of the mature DC and allowing the fragmented membrane to assemble into a CDNV displaying the MHC presenting the antigen. The CDNV can be delivered to an environment including a T cell, thereby directly activating the T cell, or indirectly activating the T cell through a bystander antigen presenting cell (APC) that uptakes the CDNV and presents the antigen. The activated T cell and produce a T cell response.
C07K 14/74 - Major histocompatibility complex [MHC]
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A microfluidic device includes a flow channel including (a) an inlet, (b) an inlet section, extending along a first tangent, (c) an intermediate spiral section, (d) an outlet section, extending along a second tangent, and (e) a three-dimensional outlet system including a plurality of outlets. The flow channel has a rectangular cross section having a height H and a width W, where H>W. The device is useful in a method for stable alignment, focusing, fractionation and separation of conventional particles as well as bioparticles (cells and vesicles) from a suspension.
B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
B01D 21/26 - Separation of sediment aided by centrifugal force
B01D 45/16 - Separating dispersed particles from gases or vapours by gravity, inertia, or centrifugal forces by centrifugal forces generated by the winding course of the gas stream
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
45.
3D MICROFLUIDIC TRANSFECTION DEVICES AND METHOD OF TRANSFECTING TARGET CELLS WITH A TRANSFECTION AGENT
A microfluidic transfection device, adapted for transfecting target cells with a transfection agent, includes a microfluidic flow channel and an electric field generator. The microfluidic device includes a flow channel for the target cells and the transfection agent suspended in a carrying solution, the flow channel having (a) an inlet, (b) bifurcation, and (c) an outlet. The electric field generator is adapted to generate an electric field across a width of the flow channel whereby the target cells continuously flowing through the flow channel are transfected with the transfection agent under combined physical perturbations including electrical field and hydro-pressure.
Methods for treating cancer are provided and include administering a radiolabeled 78-kDa glucose-regulated-protein (GRP78) binding agent (GRP78-binding agent) to a subject in need thereof. Methods for inhibiting prostate cancer growth in a subject and compositions which make use of a radiolabeled GRP78-binding agent are also provided.
This disclosure relates to an environmental-friendly and cost-efficient approach to synthesize CsPbBr3 powders in a large scale at room temperature with water. Using ultrasonication and centrifugation, CsPbBr3 nanocrystals can be obtained with green (˜522 nm) and blue (˜493 nm) emissions from the powders. The photoluminescence quantum yield of the blue-emitting nanocrystals is 80%, which is much larger than 61.4% of the CsPbBr3 nanocrystals made by an anti-solvent method. The green-emitting nanocrystals exhibit better stability than those made by the anti-solvent method over a period of 9 days. The method opens a new avenue to potentially produce inorganic and/or inorganic-organic hybrid halide perovskite nanocrystals without harmful organic solvents used in precursor solutions.
C09K 11/66 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing germanium, tin or lead
C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
Helicobacter pyloricagcagHelicobacter pyloricagcag T4SS operons, in embodiments selected from the group consisting of: CagA, CagC, CadD, CagE, CagF, CagG, CagH, CagI, CagM, CagN, CagO, CagP, CagQ, CagS, CagT, CagU, CagV, CagW, CagX, CagY, CagZ, Cag1, Cag2, Cag3, Cag4, Cag5, Cag-alpha. The one or more artificial T4SS operons, when introduced into the avirulent bacterial cell, result in a self-assembling, bi-membrane spanning secretion channel complex adapted to translocate the bioactive molecule to the target host cell. The system is adapted to translocate the substrate to a target host cell, which substrate may be a polynucleotide or protein of interest, DNA, RNA, DNA-RNA hybrids, DNA-encoded molecules, and others.
C12N 1/11 - ProtozoaCulture media therefor modified by introduction of foreign genetic material
C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
A method for making electrically-conductive yarn includes simultaneously drawing and axially twisting a starting material selected from a group consisting of intrinsically electrically-conducting fiber nonwovens and multifilament tows of intrinsically electrically-conducting fiber. The resulting yarn is a compacted, intrinsically electrically-conducting fiber material having an axial twist of between about 0.5 and about 60 degrees.
An apparatus adapted for automated device alignment in radiation therapy quality assurance, includes a base, a rotation adjustment assembly supported on the base, a tilt adjustment assembly supported on the rotation adjustment assembly, a quality assurance device supported on a cradle of the tilt adjustment assembly, a position sensor adapted to provide accurate measurements of a current position of the cradle during cradle position adjustment, and a controller configured to control operation of the rotation adjustment assembly and the tilt adjustment assembly and receive data from the position sensor respecting the current position of the cradle.
The presently-disclosed subject matter tri-coordinate Au(I) complexes, and methods of using tri-coordinate Au(I) complexes for selectively disrupting mitochondrial structure of target cancer cells.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A mortar mix and a concrete mix incorporate a stillage admixture that improves the workability of fresh concrete and advantageously modifies the properties of the hardened concrete.
A raw meal for a cement clinker, a cement clinker made from that raw meal and a process for producing a cement clinker are provided. The clinker contains mainly the hydraulically activate alpha′H-belite polymorph and calcium sulfoaluminate (ye'elimite or C4A3Ś), at the low firing temperature of 1050° C., using a combination of fluoride and boron oxide.
C04B 7/345 - Hydraulic cements not provided for in one of the groups
C04B 7/42 - Active ingredients added before, or during, the burning process
C04B 28/02 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing hydraulic cements other than calcium sulfates
54.
APPARATUS FOR PLACING A NEEDLE AT A SPECIFIC LOCATION AND DEPTH USING AN ULTRASOUND PROBE
An apparatus adapted for placing a needle at a specific location and depth using an ultrasound probe includes a needle guide with a plurality of needle guide apertures, a support, a stop locator, a syringe, a needle with one or more stops and a probe, such as an ultrasonic probe. The needle guide apertures may be oriented in a first row extending along a length of the needle guide.
A system and method are provided for capturing carbon dioxide from a flue gas. The system includes an absorber, a stripper, a cooling system and a control module. The cooling system is adapted to independently cool (a) a flue gas upstream from an absorber flue gas inlet and (b) a carbon dioxide-lean carbon capture solution being delivered to each of a plurality of lean carbon capture solution inlets at the different levels of the absorber. The control module includes a controller and a plurality of temperature sensors. The controller is responsive to the plurality of temperature sensors provided at each of the different levels of the absorber to control operation of the cooling system and thereby maintain a desired temperature profile at the different levels of the absorber to enhance rich loading of carbon dioxide from the flue gas to a carbon capture solution and reduce energy requirements for lean carbon capture solution regeneration in the stripper.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
The presently disclosed subject matter includes a composition comprising inactivated bacteria containing dsRNA targeting a lethal gene of an insect through RNA interference (RNAi) mechanism. The presently disclosed subject matter also includes a method of inducing RNAi in an insect by administering to the insect a composition comprising an inactivated bacteria containing expressed dsRNA targeting a lethal gene of the insect. The presently disclosed subject matter also includes a method of protecting a plant from an insect, comprising applying to the plant a composition comprising an inactivated bacteria containing expressed dsRNA targeting RNAi a lethal gene of the insect.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
A01N 57/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
C07C 243/32 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
58.
ANTIBODIES FOR BINDING PATHOLOGIC FORMS OF CALCINEURIN
Provided herein are antibodies, or antigen-binding portions thereof, which specifically bind to pathologic forms of calcineurin. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and methods for use of these antibodies, including methods for staining pathological tissue.
A method of treating an aortopathy is disclosed, including identifying a subject having or at risk of developing the aortopathy and reducing the expression of and/or activity of gasdermin D (GSDMD) in the subject. The method may include administering to the subject an effective amount of a GSDMD inhibitor. The GSDMD inhibitor may reduce the expression of GSDMD in the subject and/or may reduce the activity of GSDMD in the subject.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
60.
USING siRNAs AGAINST TAU CIRCULAR RNAS AS A RATIONAL THERAPY FOR ALZHEIMER'S DISEASE
The present disclosure concerns isolated double stranded (ds) silencing RNA (siRNA) to target a backsplice junction between exons 12 and 7 in the MAPT gene. The ds siRNA include at least one nucleotide from the 3′ terminus of exon 12 linked to at least one nucleotide of the 5′ terminus of exon 7, thereby overlapping the backsplice junction. Targeting the junction ensure that that ds siRNA are limited in targeting the circular RNA produced by the backsplicing while allowing normal expression of the MAPT gene.
A noncontact, multi-wavelength time-resolved laser speckle contrast imaging (MTR-LSCI) technique provides for continuous, fast and high-resolution 2D mapping of tissue blood flow (BF) and tissue blood oxygen saturation (StO2) at different depths of target tissue. MTR-LSCI illuminates the tissue with picosecond-pulsed, coherent, widefield light at least at two different wavelengths in the near-infrared range (600-1100 nm) and synchronizes a high-resolution, gated single-photon avalanche diode (SPAD) camera to capture BF and StO2 maps at different depths of target tissue, wherein the imaging depth depends on light propagation inside a tissue volume, captured by the time-gated camera. The reconstruction of BF and StO2 maps can be dramatically expedited by incorporating highly parallelized computation and convolution functions. The performance of MTR-LSCI was evaluated using head-simulating phantoms with known properties and in-vivo rodents with varied hemodynamic challenges to the brain.
A quality assurance device for a medical accelerator includes a housing having an inner radioluminescent layer adapted to provide a visual indication when contacted with invisible radiation generated by the medical accelerator. In addition, the quality assurance device includes one or more cameras located within the housing and adapted to image the inner radioluminescent layer of the housing including the visual indication.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A hydrophobic deep eutectic solvent includes a combination of at least two of (a) a hydrophobic component, (b) an acidic component, and (c) a reducing agent. The solvent is useful in a method of recovering critical metals from lithium-ion batteries. That method includes steps of: shredding the lithium-ion batteries to separate metal container and shell components from a black mass including graphite, copper, cathode, anode and electrolyte battery materials, leaching the black mass with a hydrophobic deep eutectic solvent to extract critical metals, including lithium, cobalt, nickel and manganese, and generate a pregnant hydrophobic deep eutectic solvent, and recovering the critical metals from the pregnant hydrophobic deep eutectic solvent.
Methods for treating blood-brain barrier dysfunction and methods for treating recurrent seizures in a subject involve inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX), 5-lipoxygenase (5-LOX), and cyclooxygenase-2 (COX-2).
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in Nicotiana plants and plant parts thereof are provided. The compositions comprise isolated polynucleotides and polypeptides for cytochrome P450s that are involved in the metabolic conversion of nicotine to nornicotine in these plants. Expression cassettes, vectors, plants, and plant parts thereof comprising inhibitory sequences that target expression or function of the disclosed cytochrome P450 polypeptides are also provided. Methods for the use of these novel sequences to inhibit expression or function of cytochrome P450 polypeptides involved in this metabolic conversion are also provided. The methods find use in the production of tobacco products that have reduced levels of nornicotine and its carcinogenic metabolite, NNN, and thus reduced carcinogenic potential for individuals consuming these tobacco products or exposed to secondary smoke derived from these products.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
68.
EXTRACTION OF COPPER FROM A FEED MATERIAL FOR THE PRODUCTION OF METALLIC COPPER
1nn in series, establishing a countercurrent flow in the leaching circuit, simultaneously grinding the feed material in the feed material feed stream during the leaching in at least one of the plurality of leaching vessels and recovering the copper from the lixiviant.
Disclosed are novel thiol isomerase inhibitors and their use in the prevention or treatment of the development or progression of a disease or condition involving one or more of the extracellular thiol isomerases. Further disclosed a method for preventing or treating thrombosis, a thrombotic disease, platelet aggregation, fibrin generation, an infectious disease, a viral disease, an immune disorder, inflammation, a neurologic disease, a neurodegenerative disorder, a cancer or a combination thereof in a patient, comprising: administering to the patient in need thereof a therapeutically effective amount of a compound.
C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
70.
END-SUBSTITUTED (HETERO)ACENES WITH PAIRWISE COUPLING IN CRYSTALLINE FORM FOR PURE SPIN POLARIZATION AND OPTICAL READOUT
The present disclosure concerns crystalline pairs of triethylsilyl-ethynyl tetraceno[2,3-b]thiophene and derivatives thereof. The crystallized pairs generate and maintain a high degree of spin polarization that constitutes a qubit. In some aspects, end substitution of a heterocyclic ring with a silicon-based group enforces the necessary pairwise interaction, with larger intermolecular distances between pairs in the crystal that can then produce a parallel alignment of the magnetic axes of all molecules within the crystal unit cell. In addition, end substitution provide energy level alignment between a triplet pair and the emissive singlet state which then allows for low temperature emission from the triplet pair.
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
C07D 333/78 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
71.
RECOVERY OF VALUABLE MATERIALS AND GRAPHITE FROM END-OF-LIFE LITHIUM-ION BATTERIES
A method of recovering valuable materials from a black mass of lithium ion batteries may be broadly described as including the steps of decomposing the black mass to produce a reduced black mass, extracting lithium from the reduced black mass and separating and recovering magnetic alloy materials and non-magnetic materials from the reduced black mass. An apparatus for recovering valuable materials from a black mass of lithium ion batteries includes a thermal reactor, a stirring reactor, a solid-liquid separator, an oven and a magnet-assisted vibration device.
Accordingly, the present invention relates compositions comprising synthetic HDL (sHDL) nanoparticles, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings). In particular, the present invention provides compositions comprising sHDL nanoparticles for purposes of preventing, attenuating, and/or treating sepsis and sepsis related disorders in a subject, conditions and symptoms caused by a viral infection (e.g., COVID-19)) in a subject, and conditions and symptoms caused by thrombosis in a subject.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
73.
DEVICE AND METHODS FOR MEASURING PLATELET-FIBRIN CLOT CONTRACTION KINETICS
This disclosure relates to systems and methods for the observation and/or measurement of clot formation and/or contraction. The system includes reaction chambers arranged with an image capturing device to allow for quantification of clot side-view cross-sectional area over time to determine the kinetics of clot formation and/or contraction. By varying the cellular materials and test agents included in the reaction chambers, it is possible to determine the effect of any particular component may yield on clot contraction. The system provides low-cost set-up, robust software, and multi-sample capacity, thus is a sensitive and flexible system to be used as a “workhorse” tool in a regular laboratory setting for better understanding the molecular features of how platelets mediate clot contraction, with the potential for clinical usages and/or medium throughput laboratory testing and drug screens.
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (USA)
Inventor
Markowitz, Sanford
Willson, James K.V.
Posner, Bruce
Ready, Joseph
Zhang, Yongyou
Tai, Hsin-Hsiung
Antczak, Monica
Gerson, Stanton
Bae, Kibeom
Yang, Sung Yeun
Desai, Amar
Abstract
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.
C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
C07D 213/73 - Unsubstituted amino or imino radicals
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 213/76 - Nitrogen atoms to which a second hetero atom is attached
C07D 215/08 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 207/263 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
C07D 275/03 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 277/46 - Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
75.
STRUCTURE-BASED DESIGN AND DISCOVERY OF LONG-ACTING COCAINE HYDROLASE MUTANTS WITH IMPROVED BINDING AFFINITY TO NEONATAL FC RECEPTOR FOR TREATMENT OF SUBSTANCE USE DISORDERS AND ORGANOPHOSPHORUS TOXICITY
The presently disclosed subject matter describes methods of treating cocaine use disorder and organophosphorus toxicity in which a butyrylcholinesterase fusion protein is administered to a subject in need thereof.
Tools for identifying risk of and for treating vascular contributions to cognitive impairment and dementia (VCID) and stroke-induced cognitive impairment in a subject are provided and include a method and a device that involve detecting target proteins in systemic blood sample from the subject.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
77.
LOUPE-BASED INTRAOPERATIVE FLUORESCENCE IMAGING DEVICE FOR THE GUIDANCE OF TUMOR RESECTION
This application concerns a loupe-based wearable device that is enhanced by a mounted visualization aid on the housing body of at least one of the loupe eyepieces, the aid providing a dual light source, a beam splitter, and a camera directed in the same optical path as a user's eyesight such that both visible light and fluorescent dye exciting light can be directed at a site of operation to enhance real time visualization of tissue resection.
C07D 251/58 - Preparation of melamine from cyanamide, dicyanamide or calcium cyanamide
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 43/00 - Drugs for specific purposes, not provided for in groups
79.
ANTEGRADE RETROGRADE RECON FEMORAL INTRAMEDULLARY NAIL SYSTEM
A femoral intramedullary device is capable of treating a variety of femoral bone fractures. The device includes an intramedullary nail capable of antegrade or retrograde insertion into the femur and having a shank long enough to extend into the shaft of the long bone and reach the corresponding distal area or proximal area and sockets located intermediate the ends of the shank for receiving anchoring pins or screws extended transversely or radially from the shaft of the long bone. The intramedullary nail is placed in the intramedullary canal of a portion of the bone and the screws are fixed in the radial sockets or receivers at the level of the femoral neck to provide mechanical support across the bone. Transverse screws are placed through the transverse sockets to provide additional support and secure the nail within the femur.
A method of recycling lithium-ion batteries includes steps of: roasting black mass from lithium-ion batteries to produce a reduced black mass, conducting simultaneous aqueous leaching and wet magnetic separation of the reduced black mass for (a) extracting soluble lithium species and (b) enriching metallic Ni—Co and subjecting the extracted soluble lithium species to electrochemical lithium ion purification. A system for recycling lithium ion batteries includes a roaster, an aqueous leaching and wet magnetic separator and an electrochemical lithium ion separator.
A D-tagatose spray-drying feed formulation is a mixture of D-tagatose and a functional excipient co-dissolved in a solvent to produce a excipient/D-tagatose composite having a glass transition temperature of greater than 30° C. A method of spray-drying D-tagatose includes the steps of (a) preparing the D-tagatose spray-drying formulation, (b) atomizing the D-tagatose spray-drying formulation in a drying chamber containing a hot inert processing gas and evaporating droplets to produce solid particles of excipient/D-tagatose composite and (c) separating and collecting the solid particles of excipient/D-tagatose composite from the processing gas.
A method of decreasing conversion of nicotine to nornicotine is provided herein. The methods includes administering at least one basic region/leucine zipper (bZIP) type transcription factor inhibitor to an organism in need thereof. Also provided herein is a method of decreasing conversion of nicotine to nornicotine including mutating a bZIP type transcription factor binding site on a promoter of a nicotine N-demethylase (NND). Further provided herein is a method of decreasing conversion of nicotine to nornicotine including mutating a plant genome to knockout at least one bZIP type transcription factor.
C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
C07C 233/08 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
84.
COMPOSITIONS, AND METHODS FOR INHIBITING DCN1-UBC12 INTERACTION
A compound is provided that is a modified piperidinyl urea-based inhibitors of DCN1-UBE2M interaction, a bridged or unbridged NAcM-OPT derivative compound, or a bridged and unbridged isoquinoline carboxamide derivative compound, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, is provided. Methods for treating diseases or disorders characterized by uncontrolled cellular proliferation are described including administering the compound, pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof to a subject in need thereof.
The present invention provides random multi-component polymers, methods to prepare the random multi-component polymers, methods for removing soluble species or insoluble particles from an aqueous solution, and methods for removing soluble species or insoluble particles from an aqueous solution in the human body
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A method for joule carbonization of fibers includes subjecting the fibers, made from an intrinsically electrically-conductive material, to a current density sufficient to heat the fibers to a carbonization temperature of between 900-2000° C. whereby the fibers are carbonized into carbon fibers. A method for joule graphitization of fibers includes subjecting the fibers, made from an intrinsically electrically-conductive material, to a current density sufficient to heat the fibers to a graphitization temperature of between 2400-3000° C. whereby the fibers are graphitized into graphitic carbon fiber.
D01F 9/20 - Carbon filamentsApparatus specially adapted for the manufacture thereof by decomposition of organic filaments from polyaddition, polycondensation or polymerisation products
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
89.
HOLLOW FIBER MEMBRANE FOR ENCLOSED SPACE AIR REMEDIATION
An air remediation device includes a housing including an internal chamber, an inlet, an outlet, and a potting material dividing said internal chamber into a first compartment and a second compartment. At least one hollow fiber membrane is supported by the potting material and held in the first compartment. Airborne viral particles are directed (a) through the inlet into the first compartment and then (b) through the at least one hollow fiber membrane, where the airborne viral particles are captured to produce treated air, and then the treated air is directed (c) through the second compartment before being exhausted from the housing through the outlet.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
A62B 11/00 - Devices for reconditioning breathing air in sealed rooms
B01D 53/22 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01D 53/85 - Biological processes with gas-solid contact
90.
FUNCTIONALIZED MESOPOROUS SILICA NANOPARTICLES FOR TREATMENT OF PERIODONTAL DISEASE
The present disclosure concerns mesoporous silica nanoparticles (MSNP) functionalized to cross in and out of cells and loaded with one or more therapeutics to provide a vehicle that can effectively provide localized treatment to both intracellular and extracellular space. The MSNPs provide a vehicle for adjunct treatment of periodontitis, being able to provide treatment against the microbes and to the tissue.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A subtalar nail implant system, an apparatus and spacer for such a subtalar nail implant system and methods of fusing a subtalar joint of a patient allow for primary and revision arthrodesis of the subtalar joint. The system allows for a more stable fusion construct, compression at the fusion site and immediate weight-bearing.
A carbon capture system includes: (a) an absorber having an inorganic solvent carbon dioxide capture section, a water wash section between the organic solvent carbon dioxide capture section and the inorganic solvent carbon dioxide capture section, a flue gas inlet at the organic solvent carbon dioxide capture section and a treated flue gas outlet at the inorganic solvent carbon dioxide capture section, (b) a stripper, (c) a polishing circuit, and (d) a water wash circuit. A related method of carbon capture includes sequentially subjecting the flue gas to (i) organic solvent carbon dioxide capture, (ii) water washing and (iii) inorganic solvent carbon dioxide capture.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
A bone biopsy assembly, includes (a) a lost motion receiver, (b) a trephine needle, including an elongated shaft having a first end, a second end and a lumen extending from the first end to the second end, and (c) a stylet, received for sliding movement within the lumen and the lost motion receiver. A method of procuring a bone core sample from a bone, includes steps of (a) engaging a pointed tip of a stylet into the bone to seat a cutting edge of a trephine needle in the bone, (b) unlocking the stylet to allow free sliding movement of the stylet within a lumen of the trephine needle and (c) driving the trephine needle into the bone to procure the bone core sample within the lumen of the trephine needle.
Methods to produce a polyacrylonitrile-based carbon fiber and polyacrylonitrile-based carbon fiber fabric with physical characteristic closely resembling rayon-based carbon fibers are disclosed. A polyacrylonitrile-based carbon fiber and polyacrylonitrile-based carbon fiber fabric with a unique combination of physical properties are also disclosed.
D01F 9/22 - Carbon filamentsApparatus specially adapted for the manufacture thereof by decomposition of organic filaments from polyaddition, polycondensation or polymerisation products from macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds from polyacrylonitriles
95.
ACCELERATING REPAIR OF MUCOSAL INJURY USING GOLD(III) COMPOUNDS
A method and apparatus are presented for recovering a target metal from a feed material. The method includes: contacting the feed material with a lixiviant adapted to leach target metal from a feed material feed stream in a leaching circuit having a plurality of leaching vessels V1, V2, Vn in series, establishing a countercurrent flow in the leaching circuit by delivering feed material feed stream to leaching vessel V1 and moving the feed material feed stream through the leaching circuit in a first direction toward leaching vessel Vn and delivering the lixiviant to the leaching vessel Vn and moving the lixiviant through the leaching circuit in a second direction toward leaching vessel V1, determining, by a controller, a reagent consumption rate for each of the leaching vessels V1, V2, Vn so as to validate performance, minimize left over reagent discharged from leaching vessel V1 and maximize target metal recovery from leaching vessel Vn and recovering the tar et metal from the lixiviant.
A method for fusing a tibiotalar joint of a patient with an intramedullary device while leaving an adjacent subtalar joint intact includes the steps of placing an intramedullary nail through a talus and into a tibia of the patient without violating a posterior facet of the adjacent subtalar joint and fixing the intramedullary nail to the talus and the tibia.
A composition and method for treating a subject following myocardial infarction are provided. The composition includes a non-PEGylated liposome. The method includes administering a non-PEGylated liposome to a subject in need thereof following myocardial infarction.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
99.
Generation of Hydrogen by Thermal Hydrolysis of Sodium Borohydrides
A solid state formulation adapted for hydrogen generation includes a mixture of sodium borohydride and a water storage agent that is stable below about 60° C. but adapted to release water upon heating to a temperature between about 80° C. and about 300° C. A method for generating hydrogen by heating that solid state formulation is also provided.
C01B 3/06 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents
F17C 11/00 - Use of gas-solvents or gas-sorbents in vessels
100.
GOLD(III) COMPOUNDS AND CANCER CELL-SELECTIVE MODULATION OF MITOCHONDRIAL RESPIRATION AND METABOLISM
A compound of formula (I) is provided. Useful compounds and compositions, and methods of making and methods of using such compounds and compositions. The subject matter also relates to methods of treating cancer using compounds and compositions provided.
patents
